- Home
- LCTX vs DSP Comparison
LCTX vs DSP Comparison
Compare LCTX & DSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- DSP
- Stock Information
- Founded
- LCTX 1990
- DSP 1999
- Country
- LCTX United States
- DSP United States
- Employees
- LCTX N/A
- DSP N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- DSP EDP Services
- Sector
- LCTX Health Care
- DSP Technology
- Exchange
- LCTX Nasdaq
- DSP Nasdaq
- Market Cap
- LCTX 110.2M
- DSP 291.3M
- IPO Year
- LCTX N/A
- DSP 2021
- Fundamental
- Price
- LCTX $0.55
- DSP $17.53
- Analyst Decision
- LCTX Strong Buy
- DSP Strong Buy
- Analyst Count
- LCTX 5
- DSP 7
- Target Price
- LCTX $4.80
- DSP $17.71
- AVG Volume (30 Days)
- LCTX 2.9M
- DSP 198.1K
- Earning Date
- LCTX 03-06-2025
- DSP 03-03-2025
- Dividend Yield
- LCTX N/A
- DSP N/A
- EPS Growth
- LCTX N/A
- DSP N/A
- EPS
- LCTX N/A
- DSP 0.08
- Revenue
- LCTX $8,719,000.00
- DSP $263,587,000.00
- Revenue This Year
- LCTX N/A
- DSP $28.26
- Revenue Next Year
- LCTX $41.15
- DSP $12.19
- P/E Ratio
- LCTX N/A
- DSP $230.51
- Revenue Growth
- LCTX N/A
- DSP 23.73
- 52 Week Low
- LCTX $0.48
- DSP $6.50
- 52 Week High
- LCTX $1.61
- DSP $21.74
- Technical
- Relative Strength Index (RSI)
- LCTX 47.26
- DSP 39.72
- Support Level
- LCTX $0.51
- DSP $16.78
- Resistance Level
- LCTX $0.60
- DSP $19.95
- Average True Range (ATR)
- LCTX 0.04
- DSP 0.88
- MACD
- LCTX 0.01
- DSP -0.40
- Stochastic Oscillator
- LCTX 53.85
- DSP 19.93
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.